Open AccessIn silico drug repositioning against human NRP1 to block SARS-CoV-2 host entry
Author(s) -
Şeref Gül
Publication year - 2021
Publication title -
turkish journal of biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.323
H-Index - 38
eISSN - 1303-6092
pISSN - 1300-0152
DOI - 10.3906/biy-2012-52
Subject(s) - in silico , drug repositioning , drug , pharmacology , neuropilin 1 , glimepiride , biology , fingolimod , drug discovery , computational biology , bioinformatics , metformin , biochemistry , cancer research , immunology , microbiology and biotechnology , gene , multiple sclerosis , vegf receptors , vascular endothelial growth factor , insulin
Despite COVID-19 turned into a pandemic, no approved drug for the treatment or globally available vaccine is out yet. In such a global emergency, drug repurposing approach that bypasses a costly and long-time demanding drug discovery process is an effective way in search of finding drugs for the COVID-19 treatment. Recent studies showed that SARS-CoV-2 uses neuropilin-1 (NRP1) for host entry. Here we took advantage of structural information of the NRP1 in complex with C-terminal of spike (S) protein of SARS-CoV-2 to identify drugs that may inhibit NRP1 and S protein interaction. U.S. Food and Drug Administration (FDA) approved drugs were screened using docking simulations. Among top drugs, well-tolerated drugs were selected for further analysis. Molecular dynamics (MD) simulations of drugs-NRP1 complexes were run for 100 ns to assess the persistency of binding. MM/GBSA calculations from MD simulations showed that eltrombopag, glimepiride, sitagliptin, dutasteride, and ergotamine stably and strongly bind to NRP1. In silico Alanine scanning analysis revealed that Tyr 297 , Trp 301 , and Tyr 353 amino acids of NRP1 are critical for drug binding. Validating the effect of drugs analyzed in this paper by experimental studies and clinical trials will expedite the drug discovery process for COVID-19.